1. Daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) as induction and consolidation therapy led to superior progression-free survival ...
1. Adding subcutaneous daratumumab to VRd (bortezomib, lenalidomide, and dexamethasone) induction/consolidation, and lenalidomide maintenance therapy improves progression-free survival in eligible ...
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed ...
1. Daratumumab therapy addition to bortezomib, cyclophosphamide, and dexamethasone showed improved cancer response in patients with systemic immunoglobulin light-chain amyloidosis. ...
Check out the original article from the Lancet Haematology here.
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
